Compare Adaptive Biotechnologies Corp (ADPT) vs Diamondback Energy Inc (FANG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Diamondback Energy Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.11 (market cap $3.33B), while Diamondback Energy Inc trades at $186.49 (market cap $50.79B). The key difference: Diamondback Energy Inc is far larger — about 15.3× Adaptive Biotechnologies Corp's market cap, and Diamondback Energy Inc pays a 2.44% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | FANG | |
|---|---|---|
Market Cap | $3.33B | $50.79B |
Sector | Health | Energy |
52-Week High | $22.37 | $213.69 |
52-Week Low | $10.24 | $134.53 |
Enterprise Value | $3.19B | $64.52B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Diamondback Energy (FANG) trades at $180.56, up 4.95% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth to $14.93B in 2025 but faces declining net margins. Analyst consensus is overwhelmingly bullish with a $232.10 price target, supported by positive energy sector sentiment from Zacks and Seeking Alpha as of late June 2026.
FANG offers upside potential from high analyst targets and operational cash flow strength, but risks include volatile oil prices, margin compression, and technical resistance near $175. The stock's high P/E of 177.28 reflects growth expectations, yet execution on Q2 2026 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →
